Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Clinical Lymphoma, Myeloma & Leukemia|June 7, 2025
Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient PerspectiveDeborah M Stephens, Chris Stewart, Liza Avruch, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 8, 2022
Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoringKelly J Gaffney, Theresa A Urban, Mariana Lucena, et al.
Transplantation and Cellular Therapy|June 10, 2026
Neighborhood socioeconomic disadvantage and distance from treatment center do not impact survival outcomes of patients with non-Hodgkin lymphoma and multiple myeloma treated with CAR T-cell therapiesAgrima Mian, Rafaella Litvin, Danai Dima, et al.
Blood Advances|October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemiaBrian T Hill, Shuo Ma, Clive S Zent, et al.
Haematologica|October 15, 2020
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaborationDeborah M Stephens, Ken Boucher, Elizabeth Kander, et al.
American Journal of Hematology|April 15, 2025
Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage TreatmentsFateeha Furqan, Kwang W Ahn, Manmeet Kaur, et al.
Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences|February 2, 2011
Anthropocene streams and base-level controls from historic dams in the unglaciated mid-Atlantic region, USADorothy Merritts, Robert Walter, Michael Rahnis, et al.
Muscle & Nerve|March 17, 2023
Expanded access protocol (EAP) program for access to investigational products for amyotrophic lateral sclerosis (ALS)Megan Yerton, Allison Winter, Dario Gelevski, et al.
Muscle & Nerve|June 29, 2022
An expanded access protocol of RT001 in amyotrophic lateral sclerosis-Initial experience with a lipid peroxidation inhibitorMegan Yerton, Allison Winter, Anthony Kostov, et al.
Haematologica|February 9, 2018
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisAnthony R Mato, Chadhi Nabhan, Meghan C Thompson, et al.
Pageof 3